TMPRSS2 Activates Hemagglutinin-Esterase Glycoprotein of Influenza C Virus.
Amino Acid Sequence
Animals
Antiviral Agents
/ pharmacology
Benzamidines
/ pharmacology
Cell Line
Cell Line, Tumor
Cells, Cultured
Dogs
Esters
/ pharmacology
Guanidines
/ pharmacology
Hemagglutinins, Viral
/ metabolism
Host Microbial Interactions
Humans
Influenza, Human
/ virology
Gammainfluenzavirus
/ enzymology
Madin Darby Canine Kidney Cells
Orthomyxoviridae Infections
/ virology
Serine Endopeptidases
/ metabolism
Trypsin
/ metabolism
Viral Fusion Proteins
/ metabolism
Viral Proteins
/ metabolism
HAT
HE
TMPRSS2
influenza C virus
serine protease
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
13 10 2021
13 10 2021
Historique:
pubmed:
19
8
2021
medline:
18
12
2021
entrez:
18
8
2021
Statut:
ppublish
Résumé
Influenza C virus (ICV) has only one kind of spike protein, the hemagglutinin-esterase (HE) glycoprotein. HE functions similarly to hemagglutinin (HA) and neuraminidase of the influenza A and B viruses (IAV and IBV, respectively). It has a monobasic site, which is cleaved by some host enzymes. The cleavage is essential to activating the virus, but the enzyme or enzymes in the respiratory tract have not been identified. This study investigated whether the host serine proteases, transmembrane protease serine S1 member 2 (TMPRSS2) and human airway trypsin-like protease (HAT), which reportedly cleave HA of IAV/IBV, are involved in HE cleavage. We established TMPRSS2- and HAT-expressing MDCK cells (MDCK-TMPRSS2 and MDCK-HAT). ICV showed multicycle replication with HE cleavage without trypsin in MDCK-TMPRSS2 cells as well as IAV did. The HE cleavage and multicycle replication did not appear in MDCK-HAT cells infected with ICV without trypsin, while HA cleavage and multistep growth of IAV appeared in the cells. Amino acid sequences of the HE cleavage site in 352 ICV strains were completely preserved. Camostat and nafamostat suppressed the growth of ICV and IAV in human nasal surface epithelial (HNE) cells. Therefore, this study revealed that, at least, TMPRSS2 is involved in HE cleavage and suggested that nafamostat could be a candidate for therapeutic drugs for ICV infection.
Identifiants
pubmed: 34406864
doi: 10.1128/JVI.01296-21
pmc: PMC8513465
doi:
Substances chimiques
Antiviral Agents
0
Benzamidines
0
Esters
0
Guanidines
0
Hemagglutinins, Viral
0
Viral Fusion Proteins
0
Viral Proteins
0
hemagglutinin esterase
0
camostat
0FD207WKDU
Serine Endopeptidases
EC 3.4.21.-
human airway trypsin-like protease
EC 3.4.21.-
Trypsin
EC 3.4.21.4
nafamostat
Y25LQ0H97D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0129621Subventions
Organisme : Clinical Research Division, Sendai Medical Center
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K07783
Références
J Biol Chem. 1998 May 8;273(19):11895-901
pubmed: 9565616
Trends Microbiol. 1999 Mar;7(3):99-100
pubmed: 10203834
J Infect Dis. 2006 May 1;193(9):1229-35
pubmed: 16586359
Emerg Infect Dis. 2006 Jun;12(6):881-6
pubmed: 16707041
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539
pubmed: 27550352
Viruses. 2016 Nov 26;8(12):
pubmed: 27898037
J Virol. 2016 Aug 26;90(18):8251-65
pubmed: 27384661
Virology. 1981 Sep;113(2):725-35
pubmed: 7023022
J Biol Chem. 1992 Jul 5;267(19):13573-9
pubmed: 1618859
Pulm Pharmacol Ther. 2015 Aug;33:66-74
pubmed: 26166259
Virology. 1981 Dec;115(2):361-74
pubmed: 7032055
PLoS One. 2017 Mar 30;12(3):e0174827
pubmed: 28358853
J Med Virol. 2014 May;86(5):879-85
pubmed: 24122799
Vaccine. 2012 Dec 7;30(51):7374-80
pubmed: 23072892
Pathog Dis. 2013 Nov;69(2):87-100
pubmed: 23821437
Curr Opin Virol. 2017 Jun;24:16-24
pubmed: 28414992
J Infect. 2014 Aug;69(2):182-9
pubmed: 24704348
Behring Inst Mitt. 1991 Jul;(89):177-84
pubmed: 1930096
J Virol. 2010 Jun;84(11):5605-14
pubmed: 20237084
J Virol. 2020 Oct 14;94(21):
pubmed: 32817211
J Virol. 2006 Oct;80(19):9896-8
pubmed: 16973594
Kurume Med J. 1983;30(3):121-3
pubmed: 6323821
J Virol. 2012 Jun;86(12):6537-45
pubmed: 22496216
J Virol. 2013 Jun;87(11):6150-60
pubmed: 23536651
J Virol. 1976 Jun;18(3):1147-50
pubmed: 178921
Bioorg Med Chem. 2010 Aug 1;18(15):5504-9
pubmed: 20620066
J Gen Virol. 1996 Apr;77 ( Pt 4):673-9
pubmed: 8627255
Virology. 1975 Dec;68(2):440-54
pubmed: 128196
Eur J Cell Biol. 2015 Jul-Sep;94(7-9):375-83
pubmed: 26095298
Infect Genet Evol. 2020 Jul;81:104269
pubmed: 32135195
J Virol. 1971 Nov;8(5):619-29
pubmed: 4332134
Cancer Res. 2001 Feb 15;61(4):1686-92
pubmed: 11245484
Virology. 1975 Dec;68(2):426-39
pubmed: 173078
Science. 1950 Oct 27;112(2913):495-7
pubmed: 14787444
Am J Public Health Nations Health. 1949 Feb;39(2):171-8
pubmed: 18111593
Sci Rep. 2016 Jul 08;6:29430
pubmed: 27389476
Virology. 1999 May 25;258(1):1-20
pubmed: 10329563
Vaccine. 2009 Oct 23;27(45):6324-9
pubmed: 19840668
J Virol. 2013 Dec;87(23):12552-61
pubmed: 24027332
Virus Res. 1984;1(4):281-96
pubmed: 6532004
Virology. 1985 Oct 30;146(2):221-32
pubmed: 3855244
PLoS Pathog. 2013 Feb;9(2):e1003151
pubmed: 23459660
J Biol Chem. 2002 Mar 8;277(10):8338-45
pubmed: 11756432
Virus Res. 1999 May;61(1):53-61
pubmed: 10426209
Protein Cell. 2016 Jan;7(1):28-45
pubmed: 26215728
PLoS One. 2015 Oct 20;10(10):e0141169
pubmed: 26485396
J Virol. 2014 Jan;88(1):282-91
pubmed: 24155384
Microbiol Immunol. 1987;31(11):1137-43
pubmed: 3502168
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Eur J Epidemiol. 1994 Feb;10(1):91-4
pubmed: 7957798
Microbiol Immunol. 2017 Nov;61(11):497-506
pubmed: 28940687
Am J Physiol Lung Cell Mol Physiol. 2010 Aug;299(2):L160-8
pubmed: 20543005
J Virol. 1984 Apr;50(1):118-24
pubmed: 6699942
Br Med J. 1955 Oct 22;2(4946):992-4
pubmed: 13260642
PLoS Pathog. 2013;9(12):e1003774
pubmed: 24348248
J Gen Virol. 2004 Jul;85(Pt 7):1885-1893
pubmed: 15218173
J Med Virol. 2021 Jun;93(6):3484-3495
pubmed: 33247612